Undisclosed Cardiovascular Device Program
Cardiovascular Disease
Pre-clinicalActive
Key Facts
About Transluminal Technologies
Transluminal Technologies is a U.S.-based medical device innovator operating in the cardiovascular sector. Founded in 2015, the company is developing next-generation, minimally invasive devices aimed at addressing complex cardiovascular conditions. As a private, likely pre-revenue entity, it is positioned in the competitive but high-growth structural heart and coronary intervention markets. The company's success will hinge on its ability to advance its technology through clinical validation and secure regulatory approvals and strategic partnerships.
View full company profileTherapeutic Areas
Other Cardiovascular Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Manocept Diagnostic | Navidea Biopharmaceuticals | Research |
| Undisclosed Therapeutic Program(s) | HeartcoR Solutions | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| iPSC-CM Cell Therapy | Khloris Biosciences | Research |
| Clinical Trial Integration | Aktiia | Various |
| Cardiovascular Disease Study | Arizona Research Center | Not Specified |
| Cardiovascular Clinical Trials | PanThera Bio | Not Specified |
| Undisclosed | Zecardio Therapeutics | Discovery/Pre-clinical |
| HDL/LDL Regulation | Alpha-1 Biologics | Pre-clinical |
| Cardiovascular Program | Helixomer | Research |
| Undisclosed Cardiovascular Program | inQB8 Medical Technologies | Pre-clinical |
| Undisclosed Cardiovascular Program(s) | Salubris Biotherapeutics | Clinical-stage (phase unspecified) |